资讯
Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.
Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.
A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...
GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...
GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...
Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their prescribed obesity medication, according to findings published in Obesity.
Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...
More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...
Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...
In 2025, the discourse surrounding prescription weight loss treatments is gaining momentum, fueled by increasing public awareness of GLP-1 receptor agonists, such as semaglutide and tirzepatide.
GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果